MY141978A - Pyrazolopyrimidines as cyclin dependent kinase inhibitors - Google Patents

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Info

Publication number
MY141978A
MY141978A MYPI20071386A MYPI20071386A MY141978A MY 141978 A MY141978 A MY 141978A MY PI20071386 A MYPI20071386 A MY PI20071386A MY PI20071386 A MYPI20071386 A MY PI20071386A MY 141978 A MY141978 A MY 141978A
Authority
MY
Malaysia
Prior art keywords
compounds
cyclin dependent
pyrazolopyrimidines
kinase inhibitors
dependent kinase
Prior art date
Application number
MYPI20071386A
Inventor
Timothy J Guzi
Park Haengsoon
Paruch Kamil
Michael P Dwyer
Ronald J Doll
Girijavallabhan Viyyoor Moopil
Lawrence W Dillard
Vinh D Tran
He Zhen Min
James Ray Anthony
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of MY141978A publication Critical patent/MY141978A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

IN ITS MANY EMBODIMENTS, THE PRESENT INVENTION PROVIDES A NOVEL CLASS OF PYRAZOLO [1 ,5-A ]PYRIMIDINE COMPOUNDS AS INHIBITORS OF CYCLIN DEPENDENT KINASES, METHODS OF PREPARING SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE SUCH COMPOUNDS, METHODS OF PREPARING PHARMACEUTICAL FORMULATIONS COMPRISING ONE OR MORE SUCH COMPOUNDS, AND METHODS OF TREATMENT, PREVENTION, INHIBITION, OR AMELIORATION OF ONE OR MORE DISEASES ASSOCIATED WITH THE CDKS USING SUCH COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS.
MYPI20071386A 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin dependent kinase inhibitors MY141978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40799902P 2002-09-04 2002-09-04

Publications (1)

Publication Number Publication Date
MY141978A true MY141978A (en) 2010-08-16

Family

ID=31978544

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20071386A MY141978A (en) 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MYPI20033322A MY137888A (en) 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI20033322A MY137888A (en) 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Country Status (19)

Country Link
US (3) US7074924B2 (en)
EP (1) EP1534710B1 (en)
JP (2) JP4700344B2 (en)
KR (1) KR20050057139A (en)
CN (1) CN1701074A (en)
AR (1) AR041136A1 (en)
AT (1) ATE376548T1 (en)
AU (1) AU2003268385B2 (en)
CA (1) CA2497450C (en)
DE (1) DE60317077T2 (en)
ES (1) ES2291665T3 (en)
IL (1) IL167088A (en)
MX (1) MXPA05002570A (en)
MY (2) MY141978A (en)
NZ (1) NZ539164A (en)
PE (1) PE20040999A1 (en)
TW (1) TWI335919B (en)
WO (1) WO2004022560A1 (en)
ZA (1) ZA200501852B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MY141978A (en) * 2002-09-04 2010-08-16 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
AU2004272437A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
AR049769A1 (en) * 2004-01-22 2006-09-06 Novartis Ag DERIVATIVES OF PIRAZOLO (1,5-A) PIRIMIDIN 7-IL-AMINA TO BE USED IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE
ES2368930T3 (en) 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN CINASE B (AKT).
FR2876583B1 (en) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
WO2007017678A1 (en) * 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
JP2009507843A (en) 2005-09-09 2009-02-26 シェーリング コーポレイション Aza-fused cyclin-dependent kinase inhibitors
US20090069315A1 (en) * 2006-03-08 2009-03-12 Rajeev Sivasankaran Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
WO2007118844A1 (en) * 2006-04-13 2007-10-25 Basf Se Substituted pyrazolopyrimidines, process for their preparation and their use for controlling harmful fungi and compositions comprising them
US8507673B2 (en) * 2008-12-11 2013-08-13 Emory University Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
ES2540867T3 (en) * 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as PDE10 inhibitors
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo(1,5alpha)pyrimidine-3-carboxamide as inhibitor of atr kinase
KR20150130491A (en) * 2013-03-13 2015-11-23 제넨테크, 인크. Pyrazolo compounds and uses thereof
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT3077397T (en) 2013-12-06 2020-01-22 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
MX373102B (en) 2014-06-05 2020-04-17 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
CN106699785A (en) * 2015-07-13 2017-05-24 南开大学 2-(N-oxide pyridine-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one compound as CDK4/6 inhibitor
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
MX2018006250A (en) 2015-11-18 2018-09-05 Genzyme Corp BIOMARCADOR OF POLIQUISTIC RENAL DISEASE AND USES OF THE SAME.
TW202146416A (en) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 Pyrazolotriazines
EP4717312A1 (en) * 2024-09-27 2026-04-01 Perha Pharmaceuticals Pyrazolo[1,5-a]pyrimidine derivatives useful as a medicament

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4116288Y1 (en) 1964-11-07 1966-07-28
JPS6157587A (en) * 1984-08-29 1986-03-24 Shionogi & Co Ltd Condensed heterocyclic derivative and antiulcerative
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
JP3275389B2 (en) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 4-amino (alkyl) cyclohexane-1-carboxylic acid amide compound
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
WO1995035298A1 (en) * 1994-06-21 1995-12-28 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JPH10101672A (en) * 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc Adenosine enhancer
JPH10101671A (en) * 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc Nitric oxide synthase inhibitor
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
JPH11292879A (en) 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc Carboxamide derivative
FR2805160B1 (en) 2000-02-23 2002-04-05 Oreal COMPOSITIONS FOR OXIDATION DYEING OF KERATINIC FIBERS COMPRISING N (2-HYDROXYBENZENE) -CARBRAMATE OR N- (2-HYDROXYBENZENE) -UREA AND PYRAZOLOPYRIMIDINE, AND DYEING METHODS
JP2002053466A (en) * 2000-08-08 2002-02-19 Otsuka Pharmaceut Factory Inc Apoptosis regulator
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (en) 2000-12-04 2003-04-18 Oreal COLORING COMPOSITION, PROCESS FOR OBTAINING AND USE FOR COLORING KERATINIC FIBERS
EP1345941A1 (en) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
DE10223917A1 (en) 2002-05-29 2003-12-11 Bayer Cropscience Ag New 7-amino-6-aryl-pyrazolo-(1,5-a)-pyrimidine derivatives, useful as pesticides, e.g. insecticides, acaricides, nematocides, bactericides or especially fungicides for protection of plants or materials
MY141978A (en) * 2002-09-04 2010-08-16 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
AR041136A1 (en) 2005-05-04
ZA200501852B (en) 2005-09-08
US20040116442A1 (en) 2004-06-17
WO2004022560A1 (en) 2004-03-18
KR20050057139A (en) 2005-06-16
HK1071569A1 (en) 2005-07-22
US20070275983A1 (en) 2007-11-29
US7309705B2 (en) 2007-12-18
CA2497450A1 (en) 2004-03-18
JP2010168406A (en) 2010-08-05
ES2291665T3 (en) 2008-03-01
IL167088A (en) 2010-12-30
EP1534710A1 (en) 2005-06-01
CN1701074A (en) 2005-11-23
NZ539164A (en) 2006-04-28
EP1534710B1 (en) 2007-10-24
WO2004022560A9 (en) 2005-07-07
JP4700344B2 (en) 2011-06-15
DE60317077T2 (en) 2008-07-24
TW200420564A (en) 2004-10-16
CA2497450C (en) 2011-05-31
DE60317077D1 (en) 2007-12-06
PE20040999A1 (en) 2004-12-28
US7074924B2 (en) 2006-07-11
MY137888A (en) 2009-03-31
JP2006502161A (en) 2006-01-19
TWI335919B (en) 2011-01-11
ATE376548T1 (en) 2007-11-15
US7511049B2 (en) 2009-03-31
MXPA05002570A (en) 2005-09-08
US20060173016A1 (en) 2006-08-03
AU2003268385A1 (en) 2004-03-29
AU2003268385B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
MY141978A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
NO20051647L (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO2007044449A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200407322A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
MX2009003733A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors.
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX2009011355A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors.
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
DE602006014848D1 (en) PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE DEPTHS
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009003734A (en) Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor.
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
MX2009005011A (en) Imidazopyrazines as protein kinase inhibitors.
ECSP11005642A (en) NEW PIRAZOLOPIRIMIDINAS AS CYCLINE DEPENDENT QUINASA INHIBITORS
WO2007032936A3 (en) Azafused cyclin dependent kinase inhibitors
ECSP066763A (en) NEW PIRAZOLOPIRIMIDINAS AS CYCLINE-DEPENDENT QUINASE INHIBITORS